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Goals and Background: The objective is to develop a patient-based
Harvey Bradshaw Index (P-HBI) of Crohn’s Disease (CD) activity
and to compare it with the clinician-based HBI of CD activity in
CD outpatients.
Study: Consecutive patients with CD randomly completed the P-
HBI either before or after the consultation. The gastroenterologist
assessed patient’s CD activity on the same day. Overall agreement
between HBI and P-HBI was calculated with Spearman’s r and
Mann-Whitney U test. Agreement regarding active disease versus
remission and agreement at item level was calculated by percent
agreement and Cohen’s k.
Results: One hundred eighty-one (response rate 88.3%) CD
patients participated. P-HBI and HBI showed a large correlation
(rs=0.82). The medians (interquartile range) of the total HBI (2; 0
to 4) and P-HBI (4; 1 to 7) were statistically signiﬁcantly diﬀerent
(z= 8.411; P<0.001). Fortunately, in 82.6% of the cases this
diﬀerence between clinicians and patients was not clinically sig-
niﬁcant (<3.2). The percentage agreement between clinician and
patient, judging CD as active or as in remission, was 77%, rs=
0.56, k=0.52, indicating a moderate agreement. P-HBI and HBI
on frequent extraintestinal manifestations in CD varied from less
than chance (k= 0.02) to a perfect agreement (k=1). Patients
tended to report more symptoms while completing the patient-
based questionnaire compared to what they reported to the clini-
cian during consultation.
Conclusions: The P-HBI is the ﬁrst step in developing a potential
promising tool given its adequate agreement with the original HBI
and its feasibility, especially in patients with low scores. Future
research is necessary to develop a validated patient-based version
studied in several patient populations.
Key Words: Crohn’s disease, disease activity, Harvey Bradshaw
index, inﬂammatory bowel disease validation.
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Crohn’s disease (CD) is most often diagnosed at youngage, has a chronic nature, and often requires life-long
medical treatment. According to the 2010 International
inﬂammatory bowel disease (IBD) task force meeting,
incidence and prevalence of CD is steadily increasing
worldwide.1–3 The general course of CD is extremely
unpredictable, characterized by periods of inﬂammation
and remission. Disease ﬂares can be intense and are fre-
quently accompanied by increased pain, fatigue, and diar-
rhea. Clearly, CD can severely challenge the well-being of
patients and limit their daily functioning.4 As relapse is
unpredictable and frequent, with a quarter to half of
patients relapsing annually,5,6 monitoring of disease activity
is of vital importance.
In daily clinical practice, the treating clinician assesses
disease activity in patients with CD. Frequently, clinicians
use clinical activity indices, such as CD Activity Index
(CDAI), Cape Town Index, Van Hees Index, or Harvey
Bradshaw Index (HBI), as these are essential instruments in
monitoring the course of CD.7 Currently, the CDAI is the
most widely validated index and is perceived as the golden
standard. However, the index is complex, rather imprac-
tical, and time consuming.8 Therefore, a simpliﬁed version
of the CDAI, the HBI, is also commonly used (Appendix I,
http://links.lww.com/JCG/A66).9–11 Although some prefer
the CDAI over its simpliﬁed version,9,10 studies indicate
that results from the HBI correlate well with those from the
CDAI, with correlations ranging from 0.80 to 0.93.11,12
Knowing patients’ CD activity is of great importance
in clinical practice as well as medical research. Two studies
have thus far developed a shortened assessment of CD
activity derived from the CDAI13,14 with the aim of easing
the use of the CDAI in research. However, these short
indices still require that patients record and sum up their
disease activity for 7 consecutive days using a disease
activity diary. Moreover, these indices are not translated
into direct patient-based questionnaires, the requested
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information is not well explained and the indices lack clear
general instructions. These restraints strongly limit their use
for medical research.
Hence, the ﬁrst aim of this study was to develop an
easy and undemanding patient-based questionnaire, which
measures CD activity and can be completed by patients
themselves. Therefore, we decided to use the HBI, as this
simpler index can be easily translated into a patient-based
questionnaire (P-HBI). As far as we know, this is the ﬁrst
study that develops a patient-based questionnaire of the
HBI. As the utility of patient-assessed CD activity is
dependent upon its agreement with the clinician-based
assessment, our second aim was to assess agreement
between the patient-based questionnaire, derived from the
HBI, with the original clinician-based HBI. Ultimately,
patient-based assessment of CD activity could increase the
chance of early detection of relapse and could enable the
investigation of CD on a larger scale.
METHODS
Study Population and Procedure
Consecutive patients with conﬁrmed CD attending the
IBD outpatient clinic of the Academic Medical Centre
Amsterdam, from April to December 2010, were invited to
participate in the study. Patients with insuﬃcient command
of Dutch were excluded. Participants were asked to com-
plete the patient-modiﬁed HBI (P-HBI) in the hospital. To
avoid order eﬀects a random half of the patients completed
the questionnaire before the outpatient consultation, while
the other half completed the questionnaire after the con-
sultation, wherever the consultation schedules permitted.
Three clinicians participated in the study, blinded for the
patients’ responses. They assessed CD activity during the
outpatient consultation by scoring the original HBI.
Measures
Clinician-based HBI
The clinicians completed the Dutch version of the
original HBI11 (Appendix I, http://links.lww.com/JCG/A66).
This questionnaire refers to disease symptoms during the
previous week and includes 12 items. It is composed of 5
domains: general well-being; abdominal pain; number of
liquid stools per day; abdominal mass (limited physical
examination by the clinician) and extraintestinal manifes-
tations of CD (eg, arthralgia, uveitis, erythema nodosum,
aphthous ulcer, pyoderma gangrenosum, anal ﬁssure, new
ﬁstula, and abscess). The questions concerning the 8
extraintestinal manifestations have a 2-fold “yes” or “no”
option. We added 1 instruction to the item “number of
liquid stools,” that is, “In case of a stoma, please score
deviation in comparison to its normal state.” After recod-
ing, the clinician-based HBI is able to categorize 2 types of
patients: patients with inactive disease (HBI score <5) and
patients with active disease (HBI score Z5).10,12
P-HBI
For patients, the Dutch version of the original HBI
was translated into a patient-based questionnaire (Appen-
dix II, http://links.lww.com/JCG/A67). This P-HBI was
devised by 2 medical psychologists, 1 research assistant, and
1 gastroenterologist. All items within the P-HBI refer to
symptoms during the previous week and medical termi-
nology and disease symptoms were clariﬁed. For example
“aphthous ulcers” is explained as “blister like spots in the
mouth” and “a ﬁssure” is described as “anal pain during
bowel movements. Here we are referring to pain in the anus
during the passage of stools.” The ﬁrst item about general
well-being is formulated as follows: “If you would have to
rate your general well-being by giving it a number, what
number would you choose?” (1= terrible, 10=very well).
The second item about abdominal pain is: “To what extent
did you have abdominal pain during the previous week?
Please indicate this on a scale from 0 to 10, where 0 stands
for no abdominal pain and 10 for the worst imaginable
abdominal pain.” The third item on physical examination
of abdominal mass was omitted, as we assumed that
patients cannot adequately physically examine themselves.
As a consequence, the patient-modiﬁed HBI consists of 11
items, instead of the 12 items in the clinician-based HBI.
The fourth item is the question concerning number of daily
liquid stools: “How many times on average per day did you
have diarrhea during the previous week? Diarrhea is liquid
stool that cannot be picked up (for instance with a fork).”
For the questions about the 8 well-known extraintestinal
manifestations, the response options for the patient were
3-fold: “yes,” “no,” and “I do not know.” This third
response option was added, as patients may not know
whether they have a speciﬁc manifestation or may be
unfamiliar with its speciﬁc medical terminology.
Debrieﬁng Questions
We examined the comprehensibility of the P-HBI
during a pilot study (n=3). In general, patients reported
that the questions were clear and easy to complete. Two
major improvements on the basis of patients’ feedback were
made. First, in the second question about “abdominal
pain” the scaling ranged from 1 to 10, which we changed
into a range from 0 to 10. Second, in the question about
“the number of liquid stools daily” 2 optional boxes were
added, which patients can tick when having either a stoma
or a pouch, since these can greatly aﬀect the stool. Patients
are asked to indicate how often they changed a bag in case
of a stoma or had excrement in case of a pouch on average
per day during the previous week compared to a regular
week.
Demographic and Clinical Characteristics
CD diagnosis, sex, birth date, year of diagnosis,
presence of stoma (yes/no), number of operations asso-
ciated with CD and presence (no vs. Z1) of comorbidity
unrelated to CD (ie, 12 other illnesses) were measured
through self-report.
Statistical Analysis
Assuming that 30% of patients have an active disease
and that agreement is 0.23, which is higher than chance (k
0.63 vs. 0.40), 150 patients were needed, with 80% power
and a 2-sided a of 0.05. We used standard descriptive sta-
tistics to summarize the sociodemographic and clinical
characteristics of included patients. We examined agree-
ment between HBI scores of the clinician and patient on the
total sum score and per item.
As previously indicated, the P-HBI had a third
response option from question 6 to 13, “I do not know.”
We analyzed the patients’ response “I do not know” in 3
diﬀerent manners, either by scoring it as “no,” as “yes,” or
as missing. As diﬀerences between these 3 modes of analysis
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were negligible (data not shown), we decided to consider “I
do not know” as “no” for further analysis.
Patient-Physician Agreement at Total Sum Level
First, we assessed the strength of the correlation
between the total HBI score assessed by the clinician and by
the patient using Spearman’s r. Correlation coeﬃcients
were interpreted as small (<0.3), medium (0.3 to 0.5), or
large (>0.5). Second, we compared the total HBI score
assessed by the clinician and by the patient using the Mann-
Whitney U test. Analyses were performed with and without
the item “abdominal mass.” Third, a diﬀerence of 3.2
points on the total HBI score was in a previous study
considered to be clinically signiﬁcant.12 This means that the
diﬀerence of 3.2 points is the smallest diﬀerence between the
total scores of patients and clinicians that is considered to
be clinically important. Therefore, we considered a diﬀer-
ence Z3.2 points between the HBI score assessed by the
clinician and by the patient as a clinically signiﬁcant dif-
ference, and a diﬀerence <3.2 points as not clinically sig-
niﬁcant. We thus calculated the percentage of diﬀerences
between total scores of the HBI and P-HBI that are Z3.2.
Fourth, to further measure agreement on the total HBI
score, we examined the extent to which the clinician-based
and patient-based CD activity are rated as active (HBI
score Z5) or as inactive (HBI score <5)12 and calculated
percentage agreement. In addition, we calculated the
Cohen’s k coeﬃcient because, unlike percent agreement,
Cohen’s k corrects for agreement over and above what
could be expected by chance.15–17 The Cohen’s k outcomes
were interpreted as less than chance (<0), slight (0.01 to
0.20), fair (0.21 to 0.40), moderate (0.41 to 0.60), sub-
stantial (0.61 to 0.80), and almost perfect (0.81 to 0.99)
agreement. Positive and negative predictive values were also
calculated. Fifth, to assess whether having comorbid dis-
ease inﬂuenced the total sum score on the P-HBI, 2 separate
analyses for patients with and without comorbidity were
compared.
Patient-Physician Agreement at Item Level
Furthermore, agreement between clinician and patient
was calculated on item level. For the items with categorical
response options we used Cohen’s k to measure agreement.
One item “frequency of diarrhea” is a continuous variable.
For this particular item we calculated the intraclass corre-
lation coeﬃcient (ICC) to measure agreement. The ICC
measures agreement between 2 continuous variables,
deﬁned as the proportion of true variance compared to
total variance. The interpretation of the magnitude of ICC
outcomes is similar to that of Cohen’s k. Since 1 item,
“abdominal mass,” was not included in the patient-trans-
lated HBI, agreement between clinician and patient could
not be calculated for this item.
Patient-Clinician Agreement at Total Sum
and Item Level
Possibly only the single well-being item would show
similar correlation as the total score of the P-HBI with the
HBI. Well-being could be simpler and easier to use in
clinical practice than the 11-point activity indices. There-
fore, we checked whether the well-being score (1 to 10) can
be used as a substitute for the P-HBI. This was done by
calculating the strength of the correlation between the
P-HBI item “well-being” and the total HBI scores, and
the strength of the correlation between the total scores of
the P-HBI and the total HBI scores using Spearman’s r.
Ethical Considerations
Since no ethical approval is required for the com-
pletion of nonintrusive self report questionnaires under
Dutch law, the Medical Ethical Committee of the Academic
Medical Centre exempted this project from formal
approval.
RESULTS
Patient Characteristics
From April to December 2010, 205 patients at the
outpatient IBD clinic were asked to complete the P-HBI.
Thus, patients may have come for routine follow-up or by
their own request. Twenty-four patients refused to ﬁll out
the form, because of time constraints (45.8%), lack of
motivation (25%), reading constraints (16.7%), and illness
(12.5%). In total, 181 patients (response rate 88.3%) with
CD participated in the study and completed the P-HBI
(Table 1). The median [interquartile range (IQR)] age of
participants was 41 years (30 to 52 y) and the majority was
female (62.4%). Moreover, CD was diagnosed at a median
(IQR) age of 24 years (19 to 34 y). At the time of partic-
ipation, the median (IQR) duration of CD was 12 years
(6 to 21 y). In total, 19 patients (10.5%) reported to have a
stoma and 127 patients (70.2%) had undergone at least 1
operation for CD in their lifetime. Less than half of the
patients (47%) reported to have no comorbidity, whereas
slightly more than a quarter of CD patients (27.1%)
reported to have 1 comorbid disease.
Comparison of Patient-based Versus
Clinician-based HBI
To control for order eﬀects, 74 patients (40.9%)
received the P-HBI before the outpatient visit, and 107
patients (59.1%) received the P-HBI after the outpatient
visit. The scores of patients who received the P-HBI before
TABLE 1. Sociodemographic and Clinical Patient Characteristics
Crohn’s Disease (n=181)
n (%) Median IQR
Demographic variables
Age (Median; range) 181 41 30-52
Sex
Female 113 (62.4)
Male 68 (37.6)
Clinical characteristics
Age at diagnosis 178* 24 19-34
Disease duration in years 178* 12 6-21
Stoma 19 (10.5)
No. operations
No operations 54 (29.8)
Z1 operations 127 (70.2)
Comorbidity
No comorbidity 85 (47)
1 comorbidity 49 (27.1)
2 comorbidities 23 (12.7)
Z3 comorbidities 22 (12.2)
*Numbers do not add up due to missing values.
IQR indicates interquartile range.
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versus after the outpatient visit were not signiﬁcantly dif-
ferent by the Mann-Whitney U test (z=1.7, P=0.10).
Total HBI Score
First, Spearman’s r between clinician-based and
patient-based total HBI score was 0.82, indicating a large
correlation. Second, the median (IQR) total score of the
clinician version of the HBI was 2 (0 to 4) and 4 (1 to 7) of
the patient version. These total scores were signiﬁcantly
diﬀerent according to the Mann-Whitney U test (z=8.4,
P<0.001). Repeating the comparison of the patient ver-
sion with the clinician version without the abdominal mass
item using the Mann-Whitney U test led to similar results
(z=8.6, P<0.001). Third, the diﬀerence between the total
HBI score assessed by the patient and by the clinician was not
clinically relevant (ie, <3.2 points) in 147 (82.6%) cases.
Fourth, the percentage agreement between clinician and
patient, both judging CD as active or as in remission, was
77%. Cohen’s k yielded a score of 0.52 (moderate agreement)
(Table 2 and Fig. 1). In 35 cases (19%) the P-HBI classiﬁed
disease activity as active, whereas clinicians scored the same
disease activity as inactive. In 4 cases (2%) the P-HBI
assessed disease activity as inactive, whereas clinicians con-
sidered the same disease activity as active. Positive and neg-
ative predictive values are shown in Table 2. Fifth, the stat-
istically signiﬁcant diﬀerence between patient and clinician
total HBI scores was similar for patients with and without
comorbidity (data not shown).
Item-level HBI Scores
On the ﬁrst item “well-being,” the P-HBI correlated
highly (rs=0.65) with the clinician-based HBI and yielded
a moderate agreement (k=0.52). Compared to the clini-
cian-based assessment, the P-HBI scored higher on
well-being in 20 cases, whereas patients scored lower on
well-being in 28 cases (Table 3). The second item
“abdominal pain” showed a high correlation (rs=0.53)
and a slight agreement (k= 0.14) between clinician and
patient assessment. In 109 cases patients scored “abdominal
pain” on the P-HBI higher than clinicians, whereas
abdominal pain was never scored lower by patients
(Table 4). The third item “frequency of diarrhea” yielded a
substantial agreement (ICC=0.80; 95% CI, 0.74-0.85)
between the 2 questionnaires. Agreement between the
patient-based and clinician-based HBI on frequent extra-
intestinal manifestations of CD varied from less than
chance to a perfect agreement (Table 5). Erythema nodo-
sum (k=1) yielded a perfect agreement, arthralgia
(k=0.56), active ﬁstula (k=0.49), and uveitis (k=0.49) a
moderate agreement, aphthous ulcer (k=0.35) a fair
agreement, ﬁssure (k=0.03) a slight agreement, pyoderma
(k=0) no agreement, and abscess (k= 0.02) an agree-
ment below chance. We repeated all analyses without the
patients with a pouch or a stoma. This led to similar results
(data not shown).
Patient-Clinician Agreement at Total Sum
and Item Level
The item “well-being” of the P-HBI correlated lower
with the total scores of the HBI (rs= 0.55) than the total
scores of the P-HBI (rs=0.82) did.
DISCUSSION
This study compared a patient-based P-HBI as
assessed by CD patients with the HBI as assessed by the
treating gastroenterologist. If high agreement is found, the
P-HBI can easily be applied in daily clinical practice, may
facilitate early detection of relapse, would be helpful for
large scale future research, and last but not least reinforce
patient empowerment.
Agreement Between HBI and P-HBI
The P-HBI appears to highly correlate with clinician-
derived scores on the total HBI score. Although patients
had signiﬁcantly higher HBI total scores than clinicians,
only a small percentage (17%) represented a clinically sig-
niﬁcant diﬀerence. Agreement between clinicians and
patients in assessing CD as active or as in remission was
moderate to large. Moreover, the positive predictive value
of P-HBI is noteworthy. When patients judge CD to be in
remission, in 96% of the cases clinicians will also judge the
disease as in remission. In contrast, the negative predictive
value of CD is lower. When patients assessed their disease
as active, only about half of the clinicians agreed with the
patient’s judgment.
TABLE 2. Clinician-Patient Association and Agreement on HBI Judged as in Remission or as Active
Clinician Assessment
n=177* Remission (<5) Active (Z5)
Patient assessment Remission (<5)
(=positive)
99 4 Positive predictive
value=0.96
Active (Z5)
(=negative)
35 39 Negative predictive
value=0.53
Agreement 77% rs=0.56 k=0.52
*Due to missing values.
Data are presented as frequencies unless stated otherwise.
HBI indicates Harvey Bradshaw Index; rs=Spearman rank correlation; k=Kappa.
(39) 22%
(35) 19%
(4) 2%
(4) 2%
(99) 55%
Agree: remission
Agree: active
Disagree: overestimation patient
Disagree: underestimation patient
Status not defined
FIGURE 1. Proportion of (dis)agreement regarding disease
activity.
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Agreement on Item-level HBI Scores
In addition, we looked at diﬀerences between patients
and clinicians at item level. The question on frequency of
diarrhea correlated highly between the P-HBI and HBI,
indicating that the number of stools per day can be easily
assessed by the patient. Considering the questions con-
cerning extraintestinal manifestations, erythema nodosum,
uveitis, and pyoderma were not very common among our
patients, no ﬁrm conclusion can be drawn for these items.
Other items did indicate a clear trend.
When the P-HBI and HBI diﬀer, patients report a
higher disease activity than the gastroenterologists: more
abdominal pain, more extraintestinal manifestations (ie,
arthralgia, active ﬁstula, aphthous ulcer, anal ﬁssure, and
abscess), and a lower level of well-being.
Previous studies on agreement between patients and
health care providers performed in a wide range of patient
populations and in various settings, report mixed ﬁnd-
ings.18–21 A review evaluating health care providers’ appraisal
of quality of life of patients with chronic diseases reported
that providers overestimated patients’ symptomatology.18 As
most studies included a limited number of patients these
results must be interpreted with caution. Another study
evaluating the extent of agreement between patients and
health care providers concluded that providers under-
estimated symptom intensities (eg, pain, fatigue, depression,
constipation, and diarrhea) of patients.19 Again, care must be
taken when interpreting these results, as only cancer patients
were included in this study. A recent survey on quality of life
in IBD including 2424 patients, the largest IBD study to date,
also found that patients reported more symptoms and a
larger impact of the disease on their lives than clinicians did.19
Indeed, our ﬁndings are in line with the latter 2 studies.
The discrepancies found in our study might either
reﬂect an overestimation of the patients while ﬁlling out the
questionnaire or an underestimation of the clinicians during
consultation. First, clinicians and patients have a diﬀerent
standard of comparison, as clinicians observe many
IBD patients, whereas patients lack such a comparative
perspective.18 Second, some patients may be reluctant to
answer the questions accurately when asked by a clinician.
For instance, during the consultation patients might report
less abdominal pain to avoid hospitalization or physical
examination, such as an invasive endoscopy. In addition,
patients might give socially desirable answers. This might
be particularly relevant for the item on well-being. Patients
may assume that the task of the clinician is merely to
address physical symptoms and not symptoms related to
their well-being. Alternatively, clinicians may not thor-
oughly probe patients about their well-being and only
base their judgment on physical aspects.22 Finally, dis-
crepancies in agreement between patients and clinicians
may be attributed to the level of objectivity of symptoms.
Abdominal pain and well-being are more subjective varia-
bles than diarrhea.
Patient-Clinician Agreement at Total Sum
and Item Level
Since it was assumed that the patient’s well-being score
might be easier to use in clinical practice, we checked whether
it can replace the total score of the P-HBI. However, results
show that although the well-being item moderately correlates
with the HBI total scores, the total scores of the P-HBI have
a much larger correlation with the HBI. Therefore we are in
favor of using the total scores of the P-HBI.
TABLE 3. Clinician-Patient Association and Agreement on HBI Item “Well-being” on a 10-Point Scale
Clinician Assessment
n=180* <4 4 5 6 Z7
Patient assessment <4 2 3 1 0 1
4 0 1 2 2 1
5 0 0 5 8 2
6 0 0 0 29 8
Z7 0 2 1 17 95
Agreement 73% rs=0.65 k=0.52
*Due to missing values.
Data are presented as frequencies unless stated otherwise.
HBI indicates Harvey Bradshaw Index; rs=Spearman rank correlation; k=Kappa.
TABLE 4. Clinician-Patient Association and Agreement on HBI Item “Abdominal Pain” on a 10-Point Scale
Clinician Assessment
n=179* No 1-3 4-7 8-10
Patient assessment No 49 0 0 0
1-3 52 13 0 0
4-7 26 19 8 0
8-10 3 5 4 0
Agreement 39% rs=0.53 k=0.14
*Due to missing values.
Data are presented as frequencies unless stated otherwise.
HBI indicates Harvey Bradshaw Index; rs=Spearman rank correlation; k=Kappa.
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Clinical Implications and Recommendations
for Further Research
The current study found that when CD is in remission
the clinician’s assessment can be replaced by the patient’s
assessment (P-HBI). However, when the disease is active,
only about half of the clinicians agreed with the patient’s
judgment. Therefore, when CD is active results obtained
from the P-HBI and HBI must be approached with caution.
An incorrect interpretation of symptoms may lead to
inappropriate treatment. Solely consulting the HBI or P-
HBI may result in undertreatment or overtreatment and
unnecessary symptom burden. In order to investigate which
of the 2 questionnaires is more valid, future studies should
compare the P-HBI and HBI with prospective biological
markers (eg, endoscopy or cross-sectional imaging) of dis-
ease activity in the entire sample. Furthermore, future
research is needed to investigate the inﬂuence of patient and
clinical characteristics on the agreement between patients
and physicians with respect to disease activity.
Limitations of the Study
Our study bears a few limitations. First, the compar-
ison between the patient-based and clinician-based assess-
ments of the HBI was performed in a tertiary referral
center, where severely ill CD patients are likely to be over-
represented. Therefore, our results should not be general-
ized to patients with more mild forms of CD attending
peripheral hospitals or receiving primary care. Second, as
only 3 clinicians participated in our study, generalization to
the larger clinician population might be limited. Third,
most CD extraintestinal manifestations were not very
common among our cohort of patients. Hence, future
research should replicate our study with a larger and more
heterogenous sample of clinicians and patients including
those patients with mild and severe CD and with and
without CD extraintestinal manifestations and register their
disease history (eg, medications used and Montreal Clas-
siﬁcation). Fourth, contrary to the clinicians’ version of the
HBI our P-HBI did not include the item about abdominal
mass, whereas our cut-oﬀ scores11 were based on the orig-
inal HBI that does include this item. Fortunately, the item
“abdominal mass” was scored by the clinician in only 2.7%
(n=5) of the current patient group. We repeated our
analyses with and without the abdominal mass item for
clinicians, which led to similar results. Therefore, it is
unlikely that the absence of the item on abdominal mass on
the P-HBI had a signiﬁcant impact on our ﬁndings.
Strengths
This study also has several strengths. First and fore-
most, it is the ﬁrst study that has developed a patient-based
questionnaire of the HBI, and has compared this ques-
tionnaire with a clinician-based assessment. The P-HBI can
easily be completed by patients without the presence of a
clinician allowing its use as a web-based questionnaire.
Furthermore, to the best of our knowledge, this is the ﬁrst
study evaluating the extent of patient and health care pro-
vider agreement in patients with CD, whereas 2 previous
studies evaluated the extent of agreement in patients with
ulcerative colitis.23,24 Third, our P-HBI incorporates clear
instructions and descriptions to facilitate a standardized and
undemanding patient self-administration of disease activity.
Moreover, the scoring system is simple and equivalent to the
original clinician-based HBI. A fourth strength is that the
patient-based and clinician-based assessment of the HBI
took place on the same day within a time span of an hour.
Therefore, it is to be expected that disease activity did not
change and thus that the patient-based and clinician-based
assessment captured the same CD activity. A ﬁfth strength is
that clinicians were blinded for the patients’ responses.
Finally, to control for order eﬀects patients received the P-
HBI at random before or after the consultation. Whereas
more patients completed the P-HBI after the consultations
due to clinicians’ time constraints, the potential order eﬀect
was not found to inﬂuence our results.
CONCLUSIONS
This study represents a ﬁrst step in the development of
a patient-based translation of the HBI. The current version
of this patient-based HBI has a high clinical agreement
(96%) with the clinician-based HBI when CD is in remis-
sion. The P-HBI can be used as a complementary assess-
ment of disease activity and has additional value by
enquiring into diﬀerent symptoms of disease activity and
extra intestinal manifestations. It might help the clinician to
preselect patients who have to be invited for a clinical
consult. If patients score low on the P-HBI there is a high
probability (96%) that disease activity is also low according
to the clinicians. Therefore, for these patients a clinical
consult might be postponed. However, further research is
necessary when the P-HBI indicates an active disease to
TABLE 5. Clinician-Patient Agreement on HBI Items “Extraintestinal Manifestations”
Extraintestinal Manifestations
Patient/Clinician Association
and Agreement N
% Total
Agreement
“No”
Agreement
(n)
“Yes”
Agreement
(n)
Patient Lower
Scores (n)
Patient Higher
Scores (n) rs j
Erythema nodosum 181 100 180 1 0 0 1 1
Arthralgia 179* 81 108 37 5 29 0.59 0.56
Active ﬁstula 181 93 161 7 0 13 0.57 0.49
Uveitis 181 99 178 1 1 1 0.49 0.49
Aphthous ulcer 181 96 172 2 1 6 0.39 0.35
Fissure 180* 82 147 1 2 30 0.06 0.03
Pyoderma gangrenosum 181 99 180 0 0 1 0 0
Abscess 180* 95 171 0 2 7 0.02 0.02
*Due to missing values.
HBI indicates Harvey Bradshaw Index; rs=Spearman rank correlation; k=Kappa.
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avoid placing patients at risk for undertreatment or over-
treatment. These patients with high scores need to be seen
by their clinician using the original HBI. If CD activity can
be measured without the patient having to visit the gas-
troenterologist or to undergo physical examination, this
might have a positive impact on their quality of life. Using a
self-report assessment is less demanding for patients in
routine clinical care and will facilitate clinical research.
Moreover, patient-based assessment of CD activity after
having improved the P-HBI for high scores (Z5) would
increase the chance of early detection of relapse. Fur-
thermore, the P-HBI can potentially reduce health care
costs, by reducing visits to the gastroenterologist and
requiring fewer physical examinations or laboratory tests.
Further research is essential to validate the P-HBI in a
variety of patient populations, including patients with a
recent onset of CD, before this can be used in daily clinical
practice. Moreover, future research should further explore
the reliability, validity, and responsiveness of the P-HBI by
comparing it to biological markers of disease activity.
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